| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 03/21/2002 | WO2002022114A2 Methods and compositions for the treatment and prevention of sexual dysfunction |
| 03/21/2002 | WO2002022112A2 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| 03/21/2002 | WO2002022111A2 Combination of lipoic acids and conjugated acids for treating diabetic disorders |
| 03/21/2002 | WO2002021934A1 Use of carnitine for enhancing training-induced bradycardia |
| 03/21/2002 | WO2001098324A8 Peptide conjugates modified n- and/or c-terminally by short charged peptide chains |
| 03/21/2002 | WO2001095920A8 Composition comprising clinoptolite, plant extracts and vitamin b complex for diabetic neuropathy |
| 03/21/2002 | WO2001081346A3 Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 03/21/2002 | WO2001078529A3 Compositions and methods for improving vascular health |
| 03/21/2002 | WO2001074379A3 Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors |
| 03/21/2002 | WO2001070694A8 Amorphous torasemide modification |
| 03/21/2002 | WO2001068092A3 Glycogen phosphorylase inhibitor |
| 03/21/2002 | WO2001066099A3 Use of quinazoline derivatives as angiogenesis inhibitors |
| 03/21/2002 | WO2001064715A3 Memno peptides, a process for their preparation and their use |
| 03/21/2002 | WO2001064344A3 Microfabricated devices for the storage and selective exposure of chemicals and devices |
| 03/21/2002 | WO2001062905A3 Integrin antagonists |
| 03/21/2002 | WO2001060991A3 Human kinases |
| 03/21/2002 | WO2001060402A3 Proteosome influenza vaccine |
| 03/21/2002 | WO2001060319A3 Polyhydroxylated benzene-containing compounds |
| 03/21/2002 | WO2001055106A3 Novel melanocortin receptor agonists and antagonists |
| 03/21/2002 | WO2001051638A3 Drug metabolizing enzymes |
| 03/21/2002 | WO2001047935A3 Novel bisamidate phosphonate prodrugs |
| 03/21/2002 | WO2001041812A3 Amphiphilic polymers and polypeptide conjugates comprising same |
| 03/21/2002 | WO2001035943A3 Dextrose and insulin fluid formulation for intravenous infusion |
| 03/21/2002 | WO2001035940A3 Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride |
| 03/21/2002 | WO2001032160A3 Modification of cholesterol concentrations with citrus phytochemicals |
| 03/21/2002 | WO2001030375A3 Use of gdnf for treating corneal defects |
| 03/21/2002 | WO2001012176A3 Use of monoamine oxidase inhibitors for the manufacture of drugs intended for the treatment of obesity |
| 03/21/2002 | WO2000041484A8 Novel use of phospholipids of vegetable and animal origin in nutritional therapy |
| 03/21/2002 | US20020035737 Cloning pigs using donor nuclei from differentiated cells |
| 03/21/2002 | US20020035735 Reproducing and animal; obtain preferential embryonic cells, culture cells, transfer cells to primate, recover infant |
| 03/21/2002 | US20020035386 Therapeutic light source and method |
| 03/21/2002 | US20020035267 Tetrazolyl-phenyl acetamide glucokinase activators |
| 03/21/2002 | US20020035266 Tetrazolyl-phenyl acetamide glucokinase activators |
| 03/21/2002 | US20020035264 Therapy for vision disorders |
| 03/21/2002 | US20020035262 7-hetero-bicyclo[2.2.1]-heptanes |
| 03/21/2002 | US20020035153 Kits; containing a compound containing an oxamic acid group |
| 03/21/2002 | US20020035151 Calcium formate for use as a dietary supplement |
| 03/21/2002 | US20020035147 Nervous system, psychological disorders |
| 03/21/2002 | US20020035140 1-(pyrrlolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 03/21/2002 | US20020035130 Antidepressants, therapy for Parkinson's disease |
| 03/21/2002 | US20020035125 Therapeutic combination |
| 03/21/2002 | US20020035122 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives |
| 03/21/2002 | US20020035114 Substituted dimeric compounds |
| 03/21/2002 | US20020035110 Treatment or prevention of disorders of the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, and sleep apnea |
| 03/21/2002 | US20020035106 Use of potassium channel agonists for reducing fat food consumption |
| 03/21/2002 | US20020035104 Integrin receptor inhibitors |
| 03/21/2002 | US20020035102 Azetidine derivatives, their preparation and medicaments containing them |
| 03/21/2002 | US20020035094 Substituted pyridine compounds and methods of use |
| 03/21/2002 | US20020035089 Orlistat compositions |
| 03/21/2002 | US20020035077 Pyrrolo[2,3-d]pyrimidine nucleoside analogs |
| 03/21/2002 | US20020035064 Method for treating atherosclerosis employing an aP2 inhibitor and combination |
| 03/21/2002 | US20020034546 Pharmaceutical composition containing a combination of a statin and aspirin and method |
| 03/21/2002 | US20020034513 MHC complexes and uses thereof |
| 03/21/2002 | DE10045059A1 Therapeutische Kombination von Liponsäure und Konjuensäuren zur Behandlung diabetischer Störungen The therapeutic combination of lipoic acid and conjugated fatty acids for the treatment of diabetic disorders |
| 03/21/2002 | DE10044325A1 Neue MMP-2-Derivate als Inhibitoren des Integrins avbeta3 New MMP-2 derivatives as inhibitors of the integrin avbeta3 |
| 03/21/2002 | CA2422376A1 Isoxazoles and their use as inhibitors of erk |
| 03/21/2002 | CA2422246A1 Methods and compositions for the treatment and prevention of sexual dysfunction |
| 03/21/2002 | CA2422095A1 Tweak receptor agonists as anti-angiogenic agents |
| 03/21/2002 | CA2422076A1 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 03/21/2002 | CA2422068A1 Method for treatment of insulin resistance in obesity and diabetes |
| 03/21/2002 | CA2422055A1 Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission) |
| 03/21/2002 | CA2422032A1 The diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism |
| 03/21/2002 | CA2422013A1 Substituted urea neuropeptide y y5 receptor antagonists |
| 03/21/2002 | CA2421994A1 The diagnosis, prevention, and/or treatment of atherosclerosis and underlying and/or related diseases |
| 03/21/2002 | CA2421920A1 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals |
| 03/21/2002 | CA2421792A1 Alpha v integrin receptor antagonists |
| 03/21/2002 | CA2421279A1 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | CA2421234A1 Interferon-alpha induced gene |
| 03/21/2002 | CA2420493A1 Use of carnitine for enhancing training-induced bradycardia |
| 03/21/2002 | CA2420450A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | CA2419219A1 Chemokine receptor binding heterocyclic compounds |
| 03/21/2002 | CA2418720A1 Caspase inhibitors and uses thereof |
| 03/20/2002 | EP1188765A1 Mechanism oriented inhibitors of dipeptidyl peptidase I |
| 03/20/2002 | EP1188443A1 Improved protocol for paracentesis |
| 03/20/2002 | EP1188442A2 Cinnamomi and poria composition, method to prepare the same and uses thereof |
| 03/20/2002 | EP1188438A1 Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production |
| 03/20/2002 | EP1188437A2 Beta-hydroxybutyric acid or acetoacetic acid or salts or esters therof for use in improving cerebral function |
| 03/20/2002 | EP1188383A1 Method for production of arachidonic acid |
| 03/20/2002 | EP1187912A1 In vivo insect model system for type-2 diabetes |
| 03/20/2002 | EP1187843A1 Angiogenic proteins and uses thereof |
| 03/20/2002 | EP1187838A1 Thiazolopyrimidines useful as tnf-alpha inhibitors |
| 03/20/2002 | EP1187836A1 Substituted imidazothiazoles as antidepressant agents |
| 03/20/2002 | EP1187830A1 Process for the preparation of paroxetine and structurally related compounds |
| 03/20/2002 | EP1187813A1 Azolylbenzamides and analogues and their use for treating osteoporosis |
| 03/20/2002 | EP1187639A1 Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same |
| 03/20/2002 | EP1187618A1 Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use |
| 03/20/2002 | EP1187614A1 Substituted piperidines as melanocortin-4 receptor agonists |
| 03/20/2002 | EP1187606A1 Pharmaceutical composition containing sibutramine and orlistat |
| 03/20/2002 | EP1187600A1 Method for enhancing stable cellular creatine concentration |
| 03/20/2002 | EP1187531A1 Macrophage scavenger receptor antagonists |
| 03/20/2002 | EP0937037B1 Sodium salt of [poly-(2,5-dihydroxyphenylene)]-4-thiosulphuric acid of linear structure as regulator of cell metabolism and production method thereof |
| 03/20/2002 | EP0778778B1 Probiotic compositions |
| 03/20/2002 | EP0591385B1 Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| 03/20/2002 | CN1341122A Covalently bridged insulin dimers |
| 03/20/2002 | CN1341121A Expression and export of anti-obesity proteins as Fc fusion proteins |
| 03/20/2002 | CN1341109A Polycyclic thiazole-2-ylides amines, process for the production thereof and their utilization as medicaments |
| 03/20/2002 | CN1341108A Polycyclic thiazole systems and their utilization as anorectics |
| 03/20/2002 | CN1341107A Polycyclic 2-amino-dihydrothiazole systems, process for the production thereof and their utilization as medicament |
| 03/20/2002 | CN1341099A 2-aminopyridines containing fused ring substituents |
| 03/20/2002 | CN1340355A Hypoglycemic liquid medicine for foot bath |